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| INTRODUC TI ON
Endometriosis is a benign gynecological disorder characterized by the presence and proliferation of extrauterine endometrial tissue 1 and is a risk factor for infertility. 2 Retrograde menstruation is considered to be the primary etiology, followed by the processes of attachment, invasion, proliferation and maintenance. 3 Although the underlying pathogenesis of endometriosis is still poorly understood, many cell migration-related and invasion-related molecules are associated with the progression of endometriosis.
4,5
Tensin 1 (TNS1) is a focal adhesion phosphoprotein molecule localized in cytoplasm that plays a role in the transmembrane junctions between the extracellular matrix and cytoskeleton. 6 Cells lacking TNS1 migrate more slowly than their normal counterparts, demonstrating that TNS1 is critical for normal cell migratory processes.
7
TNS1 also plays a role in cell survival, 8 apoptosis, 9 angiogenesis, 10 inflammation 11,12 and hypoxia.
13,14
Expression of the tensin family of proteins occurs in many organs, including the heart, skeletal muscles, kidneys, lungs, small intestine, liver, colon, prostate, testis, and ovaries. 15 Very low or no expression has been found in the brain, thymus, and circulating leukocytes. 15 In the gynecologic system, TNS1 is involved in implantation 16 and oogenesis, 17 and is expressed in the endometrium. 18 A phylogenetic study of ovarian endometriosis revealed that TNS1 is overexpressed in endometriotic tissue compared with eutopic tissues. 19 However, no reports to date have described the effect of hormonal treatment on TNS1 expression in women with endometriosis.
A woman's hormonal status has long been considered to be essential in the development and maintenance of endometriosis. One of the most widely used agents for the medical treatment of endometriosis is gonadotropin-releasing-hormone agonist (GnRHa). A great deal of evidence supports the efficacy of GnRHa for pain control and reducing the size of endometriotic lesions.
20,21
Thus, we sought to evaluate the effect of GnRHa on TNS1 expression in tissues and serum among women with endometriosis.
We hypothesized that TNS1 would be downregulated in women with endometriosis who receive GnRHa treatment compared with women who are not treated with GnRHa. To our knowledge, this is the first study to investigate TNS1 expression in women with endometriosis following GnRHa treatment.
| MATERIAL AND ME THODS

| Specimen collection
We recruited women scheduled for initial laparoscopic surgery for ovarian endometriosis during 2011-2016. Participants were confirmed based on histology and all had moderate-to-severe endometriosis based on the classification of the American Society for
Reproductive Medicine. 22 The participants' profiles are shown in Table 1 .
Sample collection took place in two phases. A pilot study was conducted to measure TNS1 mRNA level using 26 endometriotic tissue samples from women with endometriosis who were (n = 12)
or were not (n = 14) receiving GnRHa treatment. In the next phase, we further confirmed the pilot protein level results with a second cohort of 33 women with endometriosis who were (n = 17) or were not (n = 16) receiving GnRHa treatment. Among these 33 women, 27 contributed both tissue and serum samples, three contributed only a tissue sample, and three contributed only a serum sample.
Normal endometrial samples were obtained from 42-year-old (at proliferative phase) and 43-year-old (at secretory phase) women
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| RNA isolation and qPCR analysis
| Western blot analysis
Western blot analysis was performed to determine TNS1, estrogen receptor alpha (ERα), and estrogen receptor beta (ERβ) protein levels in endometriotic tissues. Briefly, endometriotic tissues from the treated and untreated groups were homogenized in mam- Serum samples from women with endometriosis were collected before and after GnRHa and analyzed using ELISA. BMI, body mass index; GnRHa, gonadotropin-releasing hormone agonist; tx, treatment.
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Characteristics of women with endometriosis involved in the follow-up study chemiluminescence (GE Healthcare) and quantitated with a BioSpectrum AC Imaging System (UVP, Upland, CA, USA).
| Immunohistochemistry
Immunohistochemistry was performed to localize protein expres- 
| Enzyme-linked immunosorbent assay
The blood samples from women with endometriosis were collected by peripheral venipuncture before anesthesia was administered. Serum was extracted by centrifugation at 1670 g for 10 minutes and stored at −80°C until used for ELISA. Serum levels of TNS1 were quantified using an ELISA kit (MyBioSource, San Diego, CA, USA; MBS905546) and performed according to their protocol. This assay uses anti-TNS1 capture antibody coated on a 96-well plate. Standards and samples were pipetted into the wells, and the target protein present in a sample was bound to the wells by the immobilized antibody. Unbound proteins were removed by extensive washing, and a biotinylated anti-TNS1 antibody was added. After washing, avidin-conjugated horseradish peroxidase substrate was added to the wells for color development. Level of bound TNS1 protein, in proportion to the intensity of developed color, was measured using a microplate reader at 450 nm.
A standard curve was plotted for each plate, and the serum level of TNS1 in each sample was derived by interpolation using the standard curve. Each sample was analyzed in duplicate, and the mean value was calculated. Estradiol serum level was measured by chemiluminescence immunoassay (Union Clinical Laboratory, Taipei, Taiwan).
| Statistical analyses
Data were analyzed using GraphPad PRISM version 7 for Mac (GraphPad Software, San Diego, CA, USA). Participant demographic and anthropomorphic characteristics were compared between the treated and untreated groups using unpaired samples and two-tailed t tests for continuous variables (such as age and body mass index);
discrete variables (such as dysmenorrhea, smoking and alcohol) were analyzed using Chi-square. The Mann-Whitney U test was used to compare TNS1 expression between the groups. To evaluate the concentration of TNS1 in serum in women with endometriosis before and after GnRHa treatment, we used Wilcoxon signed rank test.
Women in the follow-up group were also included in the untreated group before they received GnRHa treatment, including analyses based on menstrual cycle; their follow-up TNS1 concentrations posttreatment were also included in the treated group analyses, including duration of treatment analyses. Differences were considered to be statistically significant when P ≤ 0.05. 
| Ethical approval
| RE SULTS
| Study sample characteristics
The baseline characteristics of the participants in the two groups are summarized in Table 1 . There were no significant between-group differences in age, body mass index, dysmenorrhea, smoking or alcohol use (P > 0.05). Characteristics of the participants in the followup study, in which we assessed TNS1 serum level before and after GnRHa treatment, are described in Table 2 .
| Expression of TNS1 mRNA in endometriotic tissue
TNS1 mRNA expression was quantified in endometriotic tissue from women with endometriosis who were treated (n = 12) or not treated (n = 14) with GnRHa ( Figure 1A ). TNS1 mRNA expression in endometriotic tissue from the treated group was significantly lower than from the untreated group (P = 0.006). Further analysis of the untreated group showed that there was no significant difference between proliferative and secretory phases (P = 0.8) ( Figure 1B ). In the treated group, TNS1 mRNA did not differ significantly based on length of GnRHa administration (1 month vs ≥2 months) (P = 0.48) ( Figure 1C ).
| TNS1 protein in endometriotic tissue
Expression of TNS1 mRNA was confirmed based on protein levels.
The protein level from TNS1 mRNA was consistent with the mRNA level. Figure 2A shows that treatment with GnRHa induced downregulation of TNS1 protein compared with the control (P = 0.001).
In addition, TNS1 protein was consistent between samples taken during the proliferative and secretory phases (P = 0.6) ( Figure 2B ) in the untreated group. In the treated group, duration of GnRHa treatment of 1 month or ≥2 months did not affect the TNS1 protein level (P = 0.17) ( Figure 2C ). Furthermore, we did not find any significant differences in ERα or ERβ in protein levels in endometriotic tissues from women treated or not treated with GnRHa (Supporting Information Figure S2 ).
| Localization of TNS1
Immunohistochemistry was used to evaluate the cellular localization of TNS1 protein in normal endometrium, eutopic endometrium from women with endometriosis, and endometriotic tissues ( 
| TNS1 serum concentrations
Tensin 1 serum was measured in lower concentrations in the GnRHatreated group (n = 25) compared with the untreated group (n = 27), but this difference was not statistically significant (190.6 ± 28.75 pg/ mL vs 243.8 ± 30.02 pg/mL, respectively; P = 0.09) ( Figure 4A ). In the untreated group, we further analyzed TNS1 serum level based on menstrual phase and found no significant difference between the proliferation and secretory phases (251.7 ± 53.78 pg/mL vs 235.3 ± 25.86 pg/mL, respectively; P = 0.55) ( Figure 4B) . Duration ≥2 months (n = 9); P = 0.48. The TATA box binding protein (TBP) gene was used as an internal control. The qPCR experiment was carried out in duplicate; the bar chart shows the deviation between patients, and data are expressed as the mean ± SEM; n = number of patients. The qPCR data for TNS1 mRNA were expressed relative to TBP mRNA and normalized to the untreated group. GnRHa, gonadotropin-releasing hormone agonist; TNS1, tensin 1
of GnRHa treatment had no effect on TNS1 serum level between women treated for 1 month (211.4 ± 34.69 pg/mL) compared with ≥2 months (153.5 ± 51.03 pg/mL) (P = 0.36) ( Figure 4C ). Follow-up monitoring of TNS1 serum concentration after GnRHa treatment in 11 women showed a 53% decrease in the average concentration from pre-to posttreatment (294.9 ± 66.69 pg/mL vs 140.3 ± 55.21 pg/ mL, respectively; P = 0.003). Estradiol levels among women with endometriosis were significantly lower in the treated (17.91 ± 4.074 pg/ mL) than in the untreated group (107.7 ± 27.14 pg/mL) (P = 0.0002) (Supporting Information Figure S1A ). In the follow-up study, serum estradiol showed a significantly lower concentration (83%) from pre-to posttreatment (75.87 ± 22.33 pg/mL vs 13.11 ± 1.156 pg/ mL, respectively; P = 0.0156) ( Figure S1B ). Although serum estradiol was lower in women treated for ≥2 months (15.78 ± 2.132 pg/mL) compared with 1 month (19.43 ± 7.006 pg/mL), this difference was not statistically significant (P = 0.58) ( Figure S1C ).
| D ISCUSS I ON
This study shows that TNS1 mRNA and protein expression are downregulated in women with endometriosis following GnRHa treatment. and treatment with a high affinity estrogen receptor antagonist in the murine uterus downregulates its expression. 25 Our results reveal that women with endometriosis who received GnRHa treatment have lower estradiol levels compared with those who are untreated ( Figure S1 ). We have found that in eutopic endometrium from women with endometriosis, treatment with GnRHa induces reduced expression of ERα, but not in ERβ (Supporting Information Figure S3 ). In contrast, ERα and ERβ expressions in endometriotic tissues remained unchanged following GnRHa treatment ( Figure S2 ). This finding is consistent with a previous study showing that treatment with leuprolide acetate has no effect on ERα and ERβ expression in endometrioma. 26 With regard to broader implications, our data provide new evidence that hypoestrogenemia during GnRHa treatment may reduce the ability to express TNS1
in women with endometriosis and may thus lead to suppression of its migration. Further investigation is needed to determine the role of TNS1 in the pathogenesis of endometriosis and its relation to estrogen receptors.
We found that the serum concentration of TNS1 in GnRHatreated women with endometriosis, compared with those untreated with GnRHa, was lower ( Figure 4A ), although this difference was not statistically significant. However, in the follow-up study, serum TNS1 concentration declined significantly after GnRHa treatment ( Figure 4D ), indicating that knowing a patient's baseline TNS1 serum level may be very important for predicting how effectively GnRHa administration will reduce her serum TNS1. Ten of 11 women in the follow-up study showed a decrease in TNS1 after GnRHa treatment.
The duration of GnRHa treatment in these 11 women ranged from 1 to 2 months (Table 2) . Monitoring the within-patient serum level of this protein before and after treatment may allow improved evaluation of response to treatment compared with measuring TNS1 serum between treated and untreated groups as we did in this study.
Accordingly, we plan to follow the serum TNS1 response to GnRHa treatment in a longitudinal cohort study with a larger sample size.
Because endometriosis is a hormone-dependent disorder, we assessed whether the menstrual cycle affected TNS1 expression.
The endometrium undergoes important structural modifications, Our current investigation showed that duration of GnRHa treatment in women with endometriosis did not affect expression of TNS1 with regard to either mRNA or protein levels. Management of endometriosis with GnRHa treatment is based on its ability to induce amenorrhea and anovulation. Initially, during the first 3-4 weeks, the therapeutic response is characterized by an initial increase in gonadotropins and estradiol (referred to as a flare-up), followed by sustained hypoestrogenemia, amenorrhea and anovulation in the subsequent months. 27 Many studies have shown the effectiveness with which GnRHa induces regression of endometriosis and its clinical symptoms after 2-6 months of treatment. 27 Continuous exposure to GnRHa results in desensitization or downregulation of GnRH receptors, resulting in reduction of circulating serum gonadotropin levels and inhibition of ovarian hormone production. However, longer duration of GnRHa treatment is often associated with hypoestrogenic symptoms, including vasomotor instability, vaginal dryness and significant bone loss, which preclude its long-term use.
28
The current study suggests that TNS1 has some functions of medical interest that may make it a potential target for therapeutic intervention in endometriosis and a biomarker for the effectiveness of GnRHa treatment of this disorder. Our results require further confirmation from a larger cohort of patients and extension to include groups of control women without endometriosis and women with different stages of endometriosis to explain further the role of TNS1 in disorder progression across endometriosis subtypes. The regulatory mechanisms of TNS1 in the pathogenesis of endometriosis by GnRHa also require further elucidation. Utilizing in vivo animal models to confirm the role of TNS1 in disorder progression would also be valuable in future studies.
| CON CLUS ION
This study demonstrated a significant decrease in TNS1 expression in endometrial tissues and serum of women with endometriosis following GnRHa treatment. TNS1 expression also was stable across the menstrual cycle and independent of GnRHa treatment duration.
ACK N OWLED G EM ENTS
We thank Professor Chi-Long Chen from the Department of Pathology, Taipei Medical University Hospital, for providing normal endometrium for our immunohistochemistry experiment.
CO N FLI C T O F I NTE R E S T
The authors have no conflicts of interest in connection with the work reported herein.
O RCI D
Chii-Ruey Tzeng http://orcid.org/0000-0002-7445-0261
